- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06174753
Dapagliflozin in STEMI Randomized Clinical Trial (DAPA STEMI)
THE UNIVERSITY of OTTAWA DAPAGLIFLOZIN in STEMI RANDOMIZED CLINICAL TRIAL
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI.
Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo.
Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
Study Overview
Status
Intervention / Treatment
Detailed Description
DAPA STEMI is a single center, randomized, double-blind, parallel group study in which eligible participants with a STEMI and undergoing PPCI will be recruited and randomly assigned to dapagliflozin or placebo to take for 7 days. Participants will be prescribed study treatment i.e. dapagliflozin (10 mg) or placebo daily for 7 days.
A CMR will be obtained at day 3-5 to assess for infarct size. Participants will have follow-up visits at 30, 90, and 180 days to assess for cardiovascular events.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Poppy MacPhee, BScN
- Phone Number: 14646 6136967000
- Email: pmacphee@ottawaheart.ca
Study Contact Backup
- Name: Tanya Abarbanel
- Phone Number: 613-696-7000
- Email: tabarbanel@ottawaheart.ca
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4W7
- University of Ottawa Heart Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients referred for PPCI meeting the following criteria are eligible for the study:
- Ischemic chest discomfort of ≥30 minutes duration, and
- Onset of chest pain ≤12 hours prior to entry into the study, and
One of the following High-Risk criteria on a standard 12 lead ECG:
a. Anterior STEMI with ST-segment elevation ≥2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6) b. Extensive non-anterior STEMI defined as ST-segment elevation of >1mm in two or more contiguous non-anterior leads accompanied by i. 8 or more leads with > 1 mm ST elevation or depression, or both; OR ii. Sum of ST- segment elevation >20mm
Exclusion Criteria:
- 1. Age < 18 years 2. Any contraindication to undergo CMR imaging 3. Killip 4 (Cardiogenic shock on presentation) 4. Therapy with SGLT2i within last 8 weeks 5. Type 1 diabetes mellitus 6. Pregnancy 7. Nursing mother 8. Unwilling to use appropriate forms of contraception, as applicable 9. Chronic symptomatic HF with prior hospitalization for HF within the last year 10. Known LVEF <40% by any prior measure, documented before the current MI hospitalization 11. Known history of prior MI 12. Any non-CV condition with a life expectancy of less than one year 13. Previous randomization in the present study 14. Participation in a study with another investigational device or drug < four weeks 15. Inability to provide informed consent 16. Confirmed ketoacidosis at time of admission 17. Known severe hepatic impairment (Cirrhosis) 18. Severe renal impairment (eGFR < 30 mL/min1.73m2 (based on prior or baseline blood work) 19. Known severe valvular heart disease 20. Need for CABG within 90 days based on the results of the initial coronary angiogram 21. False positive STEMI (based on the results of the coronary angiogram)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Dapagliflozin 10mg daily X 7 days
|
Dapagliflozin 10 mg daily X 7 days
CMR 3-5 days post randomization
|
Placebo Comparator: Placebo
Placebo daily X 7 days
|
CMR 3-5 days post randomization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Infarct Size
Time Frame: 3-5 days
|
Infarct size (% of total LV mass) measured by CMR
|
3-5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Multiple Cardiac Adverse Events (MACE)
Time Frame: 3 months, and 6 months
|
A composite of death, reinfarction, stroke, or rehospitalization for HF
|
3 months, and 6 months
|
Cardiogenic Shock
Time Frame: during initial hospitalization
|
Evaluated using the SCAI classification; only class C, D, or E will be adjudicated as a secondary outcome
|
during initial hospitalization
|
Acute Kidney Injury
Time Frame: 3 months, and 6 months
|
As defined according to the KDIGO definition
|
3 months, and 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Michel LeMay, MD, Ottawa Heart Institute Research Corporation
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- ST Elevation Myocardial Infarction
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Sodium-Glucose Transporter 2 Inhibitors
- Dapagliflozin
Other Study ID Numbers
- 20230332-01H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
Clinical Trials on Dapagliflozin 10mg Tab
-
Chinese University of Hong KongRecruitingChronic Hepatitis BHong Kong
-
Seoul National University Bundang HospitalRecruitingDiabetes Type 2Korea, Republic of
-
Fondazione IRCCS Policlinico San Matteo di PaviaRecruiting
-
Region Örebro CountyLondon School of Hygiene and Tropical Medicine; Odense University Hospital; Göteborg... and other collaboratorsRecruitingAtrial Fibrillation | Chronic Coronary SyndromeDenmark, Sweden, Czechia
-
Nidae AlaaRecruitingDiabetic RetinopathyEgypt
-
Oman Ministry of HealthNot yet recruitingObesity | Weight Loss | Effect of Drug | Dapagliflozin Adverse Reaction
-
Nanjing University School of MedicineRecruiting
-
Monaldi HospitalRecruitingEfficacy | Systemic Right Ventricle | Dapagliflozin Adverse ReactionItaly
-
Albert Einstein Healthcare NetworkSuspendedAcute Kidney Injury | Percutaneous Coronary InterventionUnited States